Evaluation of the Treatment Response after Hypofractionated Radiotherapy in Patients with Advanced Head and Neck Cancers.
10.3857/jkstro.2009.27.2.55
- Author:
Won Taek KIM
1
;
Yong Kan KI
;
Ji Ho NAM
;
Dong Hyun KIM
;
Kyu Sup CHO
;
Jin Choon LEE
;
Byung Joo LEE
;
Dong Won KIM
Author Information
1. Department of Radiation Oncology, Pusan National University School of Medicine, Busan, Korea. apex7171@korea.kr
- Publication Type:Original Article
- Keywords:
Head and neck cancer;
Hypofractionation;
Radiotherapy;
Treatment response
- MeSH:
Carcinoma, Squamous Cell;
Disease-Free Survival;
Head;
Head and Neck Neoplasms;
Humans;
Neck;
Retrospective Studies
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2009;27(2):55-63
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to objectively evaluate the rate of tumor response to hypofractionated radiotherapy for advanced squamous cell carcinomas of the head and neck. MATERIALS AND METHODS: Thirty-one patients with advanced squamous cell carcinoma of the head and neck, who were treated by hypofractionated radiotherapy with 3 Gy per fraction for palliative purpose between 1998 and 2008, were reviewed retrospectively. Every tumor-volume was measured and evaluated from CT (computed tomography) images obtained before and 2~3 months after radiotherapy. The radiation toxicity was assessed during and after radiotherapy. A statistical analysis was performed to investigate overall survival, progression-free survival, and the prognostic factors for survival and response. RESULTS: The median age of the study patients was 70 years. In addition, 85% of the patients were in stage 4 cancer and 66.7% had an ECOG performance status of 1~2. The mean tumor-volume was 128.4 cc. Radiotherapy was administered with a total dose of 24~45 Gy (median: 36 Gy) over 10~25 days. Twenty-nine patients were treated with 30 Gy or more. The observed complete response rate was 12.9% and the partial response rate was 61.3%. Median survival time was 8.9 months and the 1-year progression-free survival rate was 12.9%. The treatment response rate was confirmed as a prognostic factor in the rate of survival. The primary site, stage, tumor-volume, radiotherapy field and overall radiation-dose showed a significant relationship with survival and treatment response. No grade 4 toxicity was observed during and after radiotherapy. CONCLUSION: There was an objective tumor-regression in about 74% of patients treated by hypofractionated radiotherapy. Further evaluation is needed to select the appropriate fraction-size and patient who may require the additional radiotherapy.
